Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.

The Global Fund to fight AIDS, TB and Malaria and the US President’s Emergency Plan for AIDS Relief (PEPFAR) recently ...

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...